Is insulin glargine long-acting or short-acting?
May 16, 2023
Source: Cainiu Health
Dr. Pan Yongyuan
Introduction
Insulin glargine injection is not a short-acting insulin. It is a synthetic pharmaceutical preparation, with insulin glargine as its main component. By modifying amino acids, the action of insulin is prolonged and released slowly, making it a long-acting insulin. However, self-medication is not recommended; its use should be determined according to individual conditions and under the guidance of a physician.
Generally speaking, insulin glargine injection is a long-acting insulin and not a short-acting insulin. The specific details are as follows:
Insulin glargine injection is a synthetic pharmaceutical preparation whose main component is insulin glargine. By modifying amino acids, the action of insulin is prolonged, allowing for slow release; therefore, it belongs to the category of long-acting insulins. Relevant studies have shown that this medication promotes glucose uptake in peripheral tissues such as skeletal muscle and fat, inhibits hepatic glucose production, and plays a role in regulating glucose metabolism. Additionally, it has approximately 5 to 8 times higher affinity for the human IGF-1 receptor than regular human insulin. It is commonly used clinically in diabetic patients who require insulin therapy. However, self-medication is not recommended. The drug should be used under a doctor's guidance according to individual conditions. If combination therapy with other antidiabetic agents is needed, consultation with a qualified physician or pharmacist is necessary prior to use.
If the injected dose is too high or if diet and physical activity are not properly adjusted, hypoglycemic reactions may occur. Some individuals may experience allergic reactions such as redness or itching at the injection site. Contraindications include hypersensitivity to any component of the medication and hypoglycemia. Patients experiencing adverse symptoms should seek medical attention at a hospital promptly.
